Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics

IF 3.1 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Investigation Pub Date : 2024-05-03 DOI:10.1111/jdi.14225

Tetsuaki Inokuchi, Yoshihide Fukumoto, Gendai Lee, Yoshifumi Yokomizo, Kokichi Tanaka, Michiko Chosa, Masaru Doi, Noboru Tamaki, Seiichi Goto, Kojiro Ichikawa, Kazuo Kobayashi

{"title":"Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics","authors":"Tetsuaki Inokuchi, Yoshihide Fukumoto, Gendai Lee, Yoshifumi Yokomizo, Kokichi Tanaka, Michiko Chosa, Masaru Doi, Noboru Tamaki, Seiichi Goto, Kojiro Ichikawa, Kazuo Kobayashi","doi":"10.1111/jdi.14225","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Glucagon-like peptide 1 receptor agonists (GLP1Ras) have emerged as pivotal agents in diabetes management and organ protection. However, their use is limited due to the necessity for injectable administration. The advent of the first oral GLP1Ra (oral semaglutide) in Japan since 2021 is expected to expand its usage. The aim of this study is to survey the efficacy and tolerability of oral semaglutide in clinical practice.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>We retrospectively analyzed 120 outpatients diagnosed with type 2 diabetes mellitus who had received oral semaglutide for >6 months. Changes in clinical parameters during oral semaglutide treatment from baseline to 12 months were analyzed. The inverse probability weighting method using the propensity score was used to evaluate the differences in clinical parameters at 6 months after treatment, based on the patients’ obesity levels.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Body weight (BW), glycated hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>), and alanine aminotransferase (ALT) levels at baseline decreased significantly after treatment compared with those at 12 months (<i>P</i> < 0.001, <i>P</i> < 0.001, and <i>P</i> = 0.03, respectively). The patients were divided into two groups using a cutoff baseline body mass index (BMI) of 30.3 kg/m<sup>2</sup>. Although no significant difference was observed, changes in body weight and HbA<sub>1c</sub> indicated a potentially greater decrease in the BMI ≧ 30.3 group than that in the BMI < 30.3 group (<i>P</i> = 0.07 and 0.13, respectively). Among 206 registered patients, 25 (12.1%) discontinued oral-semaglutide treatment owing to adverse effects, including gastrointestinal symptoms.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Oral semaglutide treatment demonstrates efficacy and tolerability for managing type 2 diabetes mellitus in Japan. Significant improvements in metabolic factors induced by oral semaglutide are anticipated, particularly in obese patients.</p>\n </section>\n </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 9","pages":"1202-1210"},"PeriodicalIF":3.1000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14225","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdi.14225","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Glucagon-like peptide 1 receptor agonists (GLP1Ras) have emerged as pivotal agents in diabetes management and organ protection. However, their use is limited due to the necessity for injectable administration. The advent of the first oral GLP1Ra (oral semaglutide) in Japan since 2021 is expected to expand its usage. The aim of this study is to survey the efficacy and tolerability of oral semaglutide in clinical practice.

Materials and Methods

We retrospectively analyzed 120 outpatients diagnosed with type 2 diabetes mellitus who had received oral semaglutide for >6 months. Changes in clinical parameters during oral semaglutide treatment from baseline to 12 months were analyzed. The inverse probability weighting method using the propensity score was used to evaluate the differences in clinical parameters at 6 months after treatment, based on the patients’ obesity levels.

Results

Body weight (BW), glycated hemoglobin A_1c (HbA_1c), and alanine aminotransferase (ALT) levels at baseline decreased significantly after treatment compared with those at 12 months (P < 0.001, P < 0.001, and P = 0.03, respectively). The patients were divided into two groups using a cutoff baseline body mass index (BMI) of 30.3 kg/m². Although no significant difference was observed, changes in body weight and HbA_1c indicated a potentially greater decrease in the BMI ≧ 30.3 group than that in the BMI < 30.3 group (P = 0.07 and 0.13, respectively). Among 206 registered patients, 25 (12.1%) discontinued oral-semaglutide treatment owing to adverse effects, including gastrointestinal symptoms.

Conclusions

Oral semaglutide treatment demonstrates efficacy and tolerability for managing type 2 diabetes mellitus in Japan. Significant improvements in metabolic factors induced by oral semaglutide are anticipated, particularly in obese patients.

Abstract Image

查看原文本刊更多论文

日本 2 型糖尿病患者口服塞马鲁肽的疗效和耐受性：糖尿病专科诊所的分析报告

导言胰高血糖素样肽 1 受体激动剂（GLP1Ras）已成为糖尿病管理和器官保护的关键药物。然而，由于必须注射给药，它们的使用受到了限制。自 2021 年起，日本出现了第一种口服 GLP1Ra（口服塞马鲁肽），有望扩大其使用范围。本研究的目的是调查口服塞马鲁肽在临床实践中的疗效和耐受性。材料与方法我们回顾性分析了120名门诊确诊的2型糖尿病患者，他们接受口服塞马鲁肽治疗>6个月。分析了口服塞马鲁肽治疗期间临床指标从基线到12个月的变化。结果基线时的体重（BW）、糖化血红蛋白A1c（HbA1c）和丙氨酸氨基转移酶（ALT）水平在治疗后与12个月时相比显著下降（分别为P <0.001、P <0.001和P = 0.03）。以基线体重指数（BMI）为 30.3 kg/m2 为临界值，将患者分为两组。虽然没有观察到明显差异，但体重和 HbA1c 的变化表明，BMI ≧ 30.3 组比 BMI < 30.3 组的下降幅度可能更大（P = 0.07 和 0.13）。在 206 名登记患者中，有 25 人（12.1%）因胃肠道症状等不良反应而中断了口服塞马鲁肽的治疗。预计口服塞马鲁肽可显著改善代谢因素，尤其是肥胖患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Investigation ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

9.40%

发文量

218

审稿时长

6-12 weeks

期刊介绍： Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).